Loading stock data…
Aligos Therapeutics (ALGS)
$5.42-0.14 (-2.60%)
Market OpenUpdated 1:26 PM EDT
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aligos Therapeutics, Inc. in the Healthcare sector is trading at $5.42 with a market capitalization of $32M. Wall Street consensus targets $56.29 (7 analysts), implying a +937.5% move over the next 12 months. The stock is currently near its 52-week low of $4.80, remaining 31.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +937.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.83M↑ | $169,000↓ | $741,000↓ | $965,000↑ | $311,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.93M↓ | -$21.81M↑ | -$28.36M↓ | -$18.57M↑ | -$19.24M |
| Net Income | -$23.04M↓ | -$19.88M↑ | -$31.54M↓ | -$15.86M↓ | $43.09M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$31.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-284.13%
Volume
Today's trading volume
28,269
Recent News
Aligos and Xiamen Amoytop sign deal for HBV therapy
Aligos remains eligible for up to $420m in milestones and tiered, high single-digit royalties on Amoytop’s net sales.
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.